Floatz logo

FILGRASTIM

Rhabdomyosarcoma

M.D. Anderson Cancer Centerprotein_peptidePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

40 Active assets in the Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3B
(+)-VINCRISTINE
Theodore Laetsch
Phase 2B
Inno-206
Children's National Research Institute
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Fudan University
Phase 2B

View all 50 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →